CRISPR Therapeutics to Participate in the Canaccord Genuity 41st Annual Growth Conference

Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) will participate in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 2:30 p.m. ET. The event aims to showcase the company's advancements in gene-based medicines for serious diseases using its CRISPR/Cas9 platform. A live webcast will be available on the company's website, with a replay accessible for 14 days post-event. CRISPR Therapeutics specializes in various therapeutic areas, including oncology and rare diseases, and collaborates with leading firms like Bayer and Vertex Pharmaceuticals.

ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 2:30 p.m. ET.

A live webcast of the event will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following each presentation.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com

Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com

FAQ

What is the date and time of CRISPR Therapeutics' participation in the Canaccord Genuity conference?

CRISPR Therapeutics will participate in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 2:30 p.m. ET.

Where can I watch the live webcast of the CRISPR Therapeutics event?

The live webcast of the event can be viewed on the 'Events & Presentations' page in the Investors section of the CRISPR Therapeutics website.

How long will the webcast replay be available after the event for CRISPR Therapeutics?

The replay of the webcast will be available for 14 days following the presentation.

What technology does CRISPR Therapeutics use for gene editing?

CRISPR Therapeutics uses the CRISPR/Cas9 technology for precise gene editing.

Which diseases does CRISPR Therapeutics focus on with its gene-based medicines?

CRISPR Therapeutics focuses on serious diseases including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.